OBJECTIVE: The study measured the effects of atypical antipsychotics on psychiatric and behavioral symptoms in patients with Alzheimer's disease and psychosis or agitated behavior. METHOD: The Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer's Disease (CATIE-AD) Alzheimer's disease effectiveness study included 421 outpatients with Alzheimer's disease and psychosis or agitated/aggressive behavior. Patients were assigned randomly to masked, flexible-dose treatment with olanzapine, quetiapine, risperidone, or placebo for up to 36 weeks. Patients could be randomly reassigned to a different medication at the clinician's discretion, which ended phase 1. Psychiatric and behavioral symptoms, functioning, cognition, care needs, and quality of life were measured at regular intervals. RESULTS: In relation to placebo, the last observation in phase 1 showed greater improvement with olanzapine or risperidone on the Neuropsychiatric Inventory total score, risperidone on the Clinical Global Impression of Changes, olanzapine and risperidone on the Brief Psychiatric Rating Scale (BPRS) hostile suspiciousness factor, and risperidone on the BPRS psychosis factor. There was worsening with olanzapine on the BPRS withdrawn depression factor. Among patients continuing phase 1 treatment at 12 weeks, there were no significant differences between antipsychotics and placebo on cognition, functioning, care needs, or quality of life, except for worsened functioning with olanzapine compared to placebo. CONCLUSION: In this descriptive analysis of outpatients with Alzheimer's disease in usual care settings, some clinical symptoms improved with atypical antipsychotics. Antipsychotics may be more effective for particular symptoms, such as anger, aggression, and paranoid ideas. They do not appear to improve functioning, care needs, or quality of life.
RCT Entities:
OBJECTIVE: The study measured the effects of atypical antipsychotics on psychiatric and behavioral symptoms in patients with Alzheimer's disease and psychosis or agitated behavior. METHOD: The Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer's Disease (CATIE-AD) Alzheimer's disease effectiveness study included 421 outpatients with Alzheimer's disease and psychosis or agitated/aggressive behavior. Patients were assigned randomly to masked, flexible-dose treatment with olanzapine, quetiapine, risperidone, or placebo for up to 36 weeks. Patients could be randomly reassigned to a different medication at the clinician's discretion, which ended phase 1. Psychiatric and behavioral symptoms, functioning, cognition, care needs, and quality of life were measured at regular intervals. RESULTS: In relation to placebo, the last observation in phase 1 showed greater improvement with olanzapine or risperidone on the Neuropsychiatric Inventory total score, risperidone on the Clinical Global Impression of Changes, olanzapine and risperidone on the Brief Psychiatric Rating Scale (BPRS) hostile suspiciousness factor, and risperidone on the BPRS psychosis factor. There was worsening with olanzapine on the BPRS withdrawn depression factor. Among patients continuing phase 1 treatment at 12 weeks, there were no significant differences between antipsychotics and placebo on cognition, functioning, care needs, or quality of life, except for worsened functioning with olanzapine compared to placebo. CONCLUSION: In this descriptive analysis of outpatients with Alzheimer's disease in usual care settings, some clinical symptoms improved with atypical antipsychotics. Antipsychotics may be more effective for particular symptoms, such as anger, aggression, and paranoid ideas. They do not appear to improve functioning, care needs, or quality of life.
Authors: Lon S Schneider; Pierre N Tariot; Karen S Dagerman; Sonia M Davis; John K Hsiao; M Saleem Ismail; Barry D Lebowitz; Constantine G Lyketsos; J Michael Ryan; T Scott Stroup; David L Sultzer; Daniel Weintraub; Jeffrey A Lieberman Journal: N Engl J Med Date: 2006-10-12 Impact factor: 91.245
Authors: Robert A Rosenheck; Douglas L Leslie; Jody L Sindelar; Edward A Miller; Peter N Tariot; Karen S Dagerman; Sonia M Davis; Barry D Lebowitz; Peter Rabins; John K Hsiao; Jeffery A Lieberman; Lon S Schneider Journal: Arch Gen Psychiatry Date: 2007-11
Authors: Robert J Howard; Edmund Juszczak; Clive G Ballard; Peter Bentham; Richard G Brown; Roger Bullock; Alistair S Burns; Clive Holmes; Robin Jacoby; Tony Johnson; Martin Knapp; James Lindesay; John T O'Brien; Gordon Wilcock; Cornelius Katona; Roy W Jones; Julia DeCesare; Michaela Rodger Journal: N Engl J Med Date: 2007-10-04 Impact factor: 91.245
Authors: M Saleem Ismail; Karen Dagerman; Pierre N Tariot; Shana Abbott; Sarah Kavanagh; Lon S Schneider Journal: Curr Alzheimer Res Date: 2007-07 Impact factor: 3.498
Authors: Somaia Mohamed; Robert Rosenheck; Constantine G Lyketsos; Richard Kaczynski; David L Sultzer; Lon S Schneider Journal: J Clin Psychiatry Date: 2011-09-06 Impact factor: 4.384
Authors: P B Rosenberg; M M Mielke; D Han; J S Leoutsakos; C G Lyketsos; P V Rabins; P P Zandi; J C S Breitner; M C Norton; K A Welsh-Bohmer; I H Zuckerman; G B Rattinger; R C Green; C Corcoran; J T Tschanz Journal: Int J Geriatr Psychiatry Date: 2012-02-29 Impact factor: 3.485
Authors: Paula T Trzepacz; Jeffrey Cummings; Thomas Konechnik; Tammy D Forrester; Curtis Chang; Ellen B Dennehy; Brian A Willis; Catherine Shuler; Linda B Tabas; Constantine Lyketsos Journal: Int Psychogeriatr Date: 2012-12-21 Impact factor: 3.878